AI Engines For more Details: Perplexity Kagi Labs You
Bronchodilation: Etofylline acts as a bronchodilator, meaning it relaxes the smooth muscles in the airways, leading to the dilation of bronchial passages. This action helps to alleviate bronchoconstriction and improve airflow in conditions like asthma and COPD, thereby relieving symptoms such as wheezing, coughing, and shortness of breath.
Increased Respiratory Function: By dilating the bronchial passages, etofylline improves respiratory function and may enhance oxygenation of tissues. This can result in symptomatic relief and improved exercise tolerance in individuals with respiratory conditions.
Reduced Airway Inflammation: Etofylline may possess anti-inflammatory properties, although its anti-inflammatory effects are generally less pronounced compared to corticosteroids. By reducing airway inflammation, etofylline may help to mitigate symptoms and prevent exacerbations in individuals with inflammatory airway diseases like asthma.
Mucociliary Clearance: Etofylline may enhance mucociliary clearance, which is the process by which mucus and foreign particles are cleared from the airways via the coordinated beating of cilia lining the respiratory tract. Improved clearance of mucus can help to alleviate congestion and reduce the risk of respiratory infections.
Stimulation of Respiratory Drive: Etofylline may stimulate the respiratory centers in the brainstem, leading to an increase in respiratory drive and minute ventilation. This effect can be beneficial in individuals with respiratory depression or hypoventilation.
Side Effects: Like other medications, etofylline may cause side effects in some individuals. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, and abdominal discomfort. Central nervous system effects such as headache, dizziness, and insomnia may also occur, especially at higher doses.
Cardiovascular Effects: Etofylline may have cardiovascular effects, including tachycardia (rapid heart rate) and palpitations. These effects are generally mild and transient but may be more pronounced in individuals with preexisting cardiovascular conditions or those taking other medications that affect heart rate and rhythm.
Drug Interactions: Etofylline may interact with other medications, particularly those metabolized by the cytochrome P450 enzyme system. Concurrent use of etofylline with certain antibiotics, antifungals, anticonvulsants, and other drugs may alter blood levels and increase the risk of adverse effects or reduced efficacy.
Monitoring: Patients taking etofylline may require regular monitoring of blood levels to ensure therapeutic efficacy and minimize the risk of toxicity. Monitoring may also include assessment of renal and hepatic function, as well as monitoring for signs of drug interactions or adverse effects.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.1 | 0.1 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | |
| Allergies | 0.1 | 0.1 | 0 |
| Allergy to milk products | 0.2 | 0.2 | |
| Alzheimer's disease | 0.2 | 0.3 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | 0 |
| Ankylosing spondylitis | 0.3 | -0.3 | |
| Anorexia Nervosa | 0.3 | -0.3 | |
| Asthma | 0.1 | 0.2 | -1 |
| Atherosclerosis | 0.1 | 0.1 | |
| Atrial fibrillation | 0.3 | 0.2 | 0.5 |
| Autism | 0.4 | 0.3 | 0.33 |
| Bipolar Disorder | 0.2 | 0.1 | 1 |
| Brain Trauma | 0.2 | -0.2 | |
| Carcinoma | 0.3 | 0.2 | 0.5 |
| Celiac Disease | 0.2 | 0.3 | -0.5 |
| Cerebral Palsy | 0.2 | -0.2 | |
| Chronic Fatigue Syndrome | 0.6 | 0.2 | 2 |
| Chronic Kidney Disease | 0.2 | 0 | 0 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
| Colorectal Cancer | 0.2 | 0.2 | |
| Constipation | 0.2 | 0.2 | |
| Coronary artery disease | 0.1 | 0.1 | |
| COVID-19 | 0.5 | 0.5 | 0 |
| Crohn's Disease | 0.3 | 0.3 | 0 |
| cystic fibrosis | 0.2 | -0.2 | |
| deep vein thrombosis | 0.1 | -0.1 | |
| Depression | 0.8 | 0.2 | 3 |
| Endometriosis | 0.2 | 0.1 | 1 |
| Epilepsy | 0.2 | 0.2 | 0 |
| Fibromyalgia | 0.2 | -0.2 | |
| Functional constipation / chronic idiopathic constipation | 0.3 | 0.2 | 0.5 |
| gallstone disease (gsd) | 0.1 | 0.1 | |
| Generalized anxiety disorder | 0.2 | -0.2 | |
| Graves' disease | 0.2 | 0.2 | |
| Halitosis | 0.2 | 0.2 | |
| Hashimoto's thyroiditis | 0.2 | 0.2 | 0 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.2 | |
| hyperglycemia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.2 | 0.2 | 0 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 0.1 | -0.1 | |
| Inflammatory Bowel Disease | 0.2 | 0.4 | -1 |
| Insomnia | 0.2 | 0.2 | 0 |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 0.2 | 0.2 | 0 |
| Liver Cirrhosis | 0.2 | 0.2 | 0 |
| Long COVID | 0.3 | 0.5 | -0.67 |
| Low bone mineral density | 0 | 0 | |
| Lung Cancer | 0.1 | -0.1 | |
| ME/CFS with IBS | 0.2 | -0.2 | |
| ME/CFS without IBS | 0.3 | 0.2 | 0.5 |
| Metabolic Syndrome | 0.3 | 0.2 | 0.5 |
| Mood Disorders | 0.8 | 0.3 | 1.67 |
| Multiple Sclerosis | 0.3 | 0.3 | 0 |
| Multiple system atrophy (MSA) | 0.1 | -0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | -0.3 | |
| Obesity | 0.2 | 0.2 | 0 |
| obsessive-compulsive disorder | 0.3 | 0.2 | 0.5 |
| Osteoarthritis | 0.2 | 0.1 | 1 |
| Osteoporosis | 0.3 | 0.2 | 0.5 |
| Parkinson's Disease | 0.1 | 0.1 | 0 |
| Polycystic ovary syndrome | 0.2 | 0.1 | 1 |
| Psoriasis | 0.1 | 0.2 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.3 | 0.2 | 0.5 |
| Rosacea | 0.1 | 0.1 | |
| Schizophrenia | 0.3 | 0.1 | 2 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0.2 | -0.2 | |
| Sleep Apnea | 0.1 | 0.2 | -1 |
| Stress / posttraumatic stress disorder | 0.2 | 0.3 | -0.5 |
| Systemic Lupus Erythematosus | 0.2 | 0.1 | 1 |
| Tic Disorder | 0.1 | 0.1 | |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 0.2 | 0 | 0 |
| Type 2 Diabetes | 0.3 | 0.2 | 0.5 |
| Ulcerative colitis | 0.2 | 0.2 | 0 |
| Unhealthy Ageing | 0.2 | 0.2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.